Go Pro
→ Ready to give options a try? Your first trade (Ticker included) -INSIDE (From Base Camp Trading) (Ad)tc pixel Free SPEC Stock Alerts

INSPECS Group (SPEC) Competitors

INSPECS Group logo
GBX 95 +1.50 (+1.60%)
As of 09/25/2026 03:14 AM Eastern
Compare

SPEC vs. NIOX, TSTL, EKF, CREO, and IUG

Should you buy INSPECS Group stock or one of its competitors? INSPECS Group's main competitors and comparable companies include NIOX Group (NIOX), Tristel (TSTL), EKF Diagnostics (EKF), Creo Medical Group (CREO), and Intelligent Ultrasound Group (IUG). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare equipment & supplies" industry.

How does INSPECS Group compare to NIOX Group?

INSPECS Group (LON:SPEC) and NIOX Group (LON:NIOX) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, earnings, institutional ownership, risk, dividends, media sentiment, valuation and profitability.

NIOX Group has lower revenue, but higher earnings than INSPECS Group. INSPECS Group is trading at a lower price-to-earnings ratio than NIOX Group, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
INSPECS Group£193.23M0.54-£4.11M-£9.40N/A
NIOX Group£48.70M5.67£995.88M£1.6440.00

In the previous week, INSPECS Group's average media sentiment score of 0.00 equaled NIOX Group'saverage media sentiment score.

Company Overall Sentiment
INSPECS Group Neutral
NIOX Group Neutral

NIOX Group has a consensus price target of GBX 86, suggesting a potential upside of 31.10%. Given NIOX Group's stronger consensus rating and higher possible upside, analysts plainly believe NIOX Group is more favorable than INSPECS Group.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
INSPECS Group
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
NIOX Group
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00

INSPECS Group has a beta of 1.603, meaning that its stock price is 60% more volatile than the broader market. Comparatively, NIOX Group has a beta of 0.92, meaning that its stock price is 8% less volatile than the broader market.

0.2% of INSPECS Group shares are held by institutional investors. Comparatively, 7.6% of NIOX Group shares are held by institutional investors. 19.6% of INSPECS Group shares are held by insiders. Comparatively, 5.1% of NIOX Group shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

NIOX Group has a net margin of 14.37% compared to INSPECS Group's net margin of -0.52%. NIOX Group's return on equity of 10.14% beat INSPECS Group's return on equity.

Company Net Margins Return on Equity Return on Assets
INSPECS Group-0.52% -1.19% 0.45%
NIOX Group 14.37%10.14%3.95%

Summary

NIOX Group beats INSPECS Group on 11 of the 14 factors compared between the two stocks.

How does INSPECS Group compare to Tristel?

Tristel (LON:TSTL) and INSPECS Group (LON:SPEC) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, profitability, valuation, media sentiment, earnings, dividends and risk.

22.4% of Tristel shares are held by institutional investors. Comparatively, 0.2% of INSPECS Group shares are held by institutional investors. 21.0% of Tristel shares are held by company insiders. Comparatively, 19.6% of INSPECS Group shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Tristel has higher earnings, but lower revenue than INSPECS Group. INSPECS Group is trading at a lower price-to-earnings ratio than Tristel, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Tristel£49.54M3.97£6.54M£16.2425.18
INSPECS Group£193.23M0.54-£4.11M-£9.40N/A

Tristel has a beta of 0.344, suggesting that its stock price is 66% less volatile than the broader market. Comparatively, INSPECS Group has a beta of 1.603, suggesting that its stock price is 60% more volatile than the broader market.

Tristel has a net margin of 15.88% compared to INSPECS Group's net margin of -0.52%. Tristel's return on equity of 23.64% beat INSPECS Group's return on equity.

Company Net Margins Return on Equity Return on Assets
Tristel15.88% 23.64% 9.89%
INSPECS Group -0.52%-1.19%0.45%

In the previous week, Tristel's average media sentiment score of 0.00 equaled INSPECS Group'saverage media sentiment score.

Company Overall Sentiment
Tristel Neutral
INSPECS Group Neutral

Summary

Tristel beats INSPECS Group on 9 of the 11 factors compared between the two stocks.

How does INSPECS Group compare to EKF Diagnostics?

INSPECS Group (LON:SPEC) and EKF Diagnostics (LON:EKF) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, media sentiment, risk, profitability, institutional ownership, analyst recommendations, earnings and valuation.

EKF Diagnostics has a consensus target price of GBX 35, suggesting a potential upside of 43.44%. Given EKF Diagnostics' stronger consensus rating and higher possible upside, analysts clearly believe EKF Diagnostics is more favorable than INSPECS Group.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
INSPECS Group
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
EKF Diagnostics
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00

INSPECS Group has a beta of 1.603, indicating that its share price is 60% more volatile than the broader market. Comparatively, EKF Diagnostics has a beta of 0.499, indicating that its share price is 50% less volatile than the broader market.

EKF Diagnostics has lower revenue, but higher earnings than INSPECS Group. INSPECS Group is trading at a lower price-to-earnings ratio than EKF Diagnostics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
INSPECS Group£193.23M0.54-£4.11M-£9.40N/A
EKF Diagnostics£51.35M2.03£4.68M£0.4751.91

EKF Diagnostics has a net margin of 4.86% compared to INSPECS Group's net margin of -0.52%. EKF Diagnostics' return on equity of 3.58% beat INSPECS Group's return on equity.

Company Net Margins Return on Equity Return on Assets
INSPECS Group-0.52% -1.19% 0.45%
EKF Diagnostics 4.86%3.58%5.27%

In the previous week, EKF Diagnostics had 2 more articles in the media than INSPECS Group. MarketBeat recorded 2 mentions for EKF Diagnostics and 0 mentions for INSPECS Group. INSPECS Group's average media sentiment score of 0.00 equaled EKF Diagnostics'average media sentiment score.

Company Overall Sentiment
INSPECS Group Neutral
EKF Diagnostics Neutral

0.2% of INSPECS Group shares are owned by institutional investors. Comparatively, 22.2% of EKF Diagnostics shares are owned by institutional investors. 19.6% of INSPECS Group shares are owned by company insiders. Comparatively, 40.2% of EKF Diagnostics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

EKF Diagnostics beats INSPECS Group on 13 of the 15 factors compared between the two stocks.

How does INSPECS Group compare to Creo Medical Group?

INSPECS Group (LON:SPEC) and Creo Medical Group (LON:CREO) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, earnings, media sentiment, analyst recommendations, institutional ownership, profitability, valuation and risk.

In the previous week, INSPECS Group's average media sentiment score of 0.00 equaled Creo Medical Group'saverage media sentiment score.

Company Overall Sentiment
INSPECS Group Neutral
Creo Medical Group Neutral

Creo Medical Group has a net margin of 88.33% compared to INSPECS Group's net margin of -0.52%. Creo Medical Group's return on equity of 9.56% beat INSPECS Group's return on equity.

Company Net Margins Return on Equity Return on Assets
INSPECS Group-0.52% -1.19% 0.45%
Creo Medical Group 88.33%9.56%-20.09%

INSPECS Group has higher revenue and earnings than Creo Medical Group. INSPECS Group is trading at a lower price-to-earnings ratio than Creo Medical Group, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
INSPECS Group£193.23M0.54-£4.11M-£9.40N/A
Creo Medical Group£6M10.10-£25.04M£1.0012.47

INSPECS Group has a beta of 1.603, indicating that its stock price is 60% more volatile than the broader market. Comparatively, Creo Medical Group has a beta of 1.563854, indicating that its stock price is 56% more volatile than the broader market.

0.2% of INSPECS Group shares are owned by institutional investors. Comparatively, 44.1% of Creo Medical Group shares are owned by institutional investors. 19.6% of INSPECS Group shares are owned by company insiders. Comparatively, 7.0% of Creo Medical Group shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Creo Medical Group beats INSPECS Group on 6 of the 11 factors compared between the two stocks.

How does INSPECS Group compare to Intelligent Ultrasound Group?

INSPECS Group (LON:SPEC) and Intelligent Ultrasound Group (LON:IUG) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their media sentiment, risk, earnings, institutional ownership, dividends, analyst recommendations, valuation and profitability.

Intelligent Ultrasound Group has lower revenue, but higher earnings than INSPECS Group. INSPECS Group is trading at a lower price-to-earnings ratio than Intelligent Ultrasound Group, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
INSPECS Group£193.23M0.54-£4.11M-£9.40N/A
Intelligent Ultrasound Group£6.57M0.00-£2.27M-£0.68N/A

INSPECS Group has a beta of 1.603, suggesting that its share price is 60% more volatile than the broader market. Comparatively, Intelligent Ultrasound Group has a beta of 0.38, suggesting that its share price is 62% less volatile than the broader market.

0.2% of INSPECS Group shares are held by institutional investors. Comparatively, 75.5% of Intelligent Ultrasound Group shares are held by institutional investors. 19.6% of INSPECS Group shares are held by company insiders. Comparatively, 12.8% of Intelligent Ultrasound Group shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

In the previous week, INSPECS Group's average media sentiment score of 0.00 equaled Intelligent Ultrasound Group'saverage media sentiment score.

Company Overall Sentiment
INSPECS Group Neutral
Intelligent Ultrasound Group Neutral

INSPECS Group has a net margin of -0.52% compared to Intelligent Ultrasound Group's net margin of -23.11%. INSPECS Group's return on equity of -1.19% beat Intelligent Ultrasound Group's return on equity.

Company Net Margins Return on Equity Return on Assets
INSPECS Group-0.52% -1.19% 0.45%
Intelligent Ultrasound Group -23.11%-23.58%-13.51%

Summary

INSPECS Group beats Intelligent Ultrasound Group on 7 of the 10 factors compared between the two stocks.

Get INSPECS Group News Delivered to You Automatically

Sign up to receive the latest news and ratings for SPEC and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SPEC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

SPEC vs. The Competition

Export
MetricINSPECS GroupHealthcare Equipment & Supplies IndustryHealthcare SectorLON Exchange
Market Cap£102.08M£5.56B£7.33B£2.89B
Dividend Yield2.00%1.79%2.52%6.21%
P/E Ratio-10.1125.31275.82366.48
Price / Sales0.5472.45638.6489,848.70
Price / Cash1.6332.9179.5227.89
Price / Book0.955.7710.446.35
Net Income-£4.11M£151.55M£3.51B£5.89B
7 Day Performance3.26%-0.97%-1.31%0.28%
1 Month Performance-1.86%-4.40%-4.61%5.51%
1 Year Performance141.36%7.68%15.01%18.75%

INSPECS Group Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
SPEC
INSPECS Group
N/AGBX 95
+1.6%		N/A+141.4%£102.08M£193.23MN/A1,673
NIOX
NIOX Group
N/AGBX 67.20
+1.8%		GBX 86
+28.0%		-10.4%£277.77M£48.70M40.9892
TSTL
Tristel
N/AGBX 395
flat		N/A+11.5%£189.89M£49.54M24.32208
EKF
EKF Diagnostics
1.996 of 5 stars		GBX 26
+1.2%		GBX 35
+34.6%		-18.4%£110.04M£51.35M55.32356
CREO
Creo Medical Group
N/AGBX 12
-1.0%		GBX 40
+233.3%		+2.0%£58.90M£6M12.00279

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (LON:SPEC) was last updated on 9/27/2026 by MarketBeat.com Staff.
From Our Partners
ALERT: Drop these 5 stocks before the market opens tomorrow!
The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...
Weiss Ratings | Sponsoredtc pixel
Small Colorado Company (Backed by Sam Altman) Could Save U.S. Power Grid
A small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...
Altimetry | Sponsoredtc pixel
Ready to give options a try? Your first trade (Ticker included) -INSIDE
Tired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...
Base Camp Trading | Sponsoredtc pixel
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
Here’s the stock symbol I’ve promised
Whitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...
Stansberry Research | Sponsoredtc pixel
Here’s Why Trump Won’t End The Iran War
Trump has called an Iran deal close 38 times since the war began, yet the fighting keeps flaring back up. O...
Banyan Hill Publishing | Sponsoredtc pixel
Bank of America: 'Digital Dollar Inevitable'
Bank of America just revealed your expiration date. In their Bloomberg interview, they didn't just predict the...
Decentralized Masters | Sponsoredtc pixel
These gold assets are priced for $1,800 gold [it's over $4,000]
Gold's major miners are generating record free cash flow, with margins as high as 75 percent even after gold's...
Golden Portfolio | Sponsoredtc pixel